An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer

Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report

“… 4 On the basis of an encouraging efficacy, alectinib has been approved for the treatment of patients with metastatic ALK -positive NSCLC. 5 Nevertheless, little is known about the efficacy of ALK TKIs for patients synchronized with SMARCA4-UT. Here, we describe the first case of a nonsmoking female diagnosed with having SMARCA4-UT with concomitant EMLA4-ALK fusion.…”